+ More
Technology
Collaborations
News Room
Contact Us

New Data Suggests Potential Reductions to Current Barriers in Continuous Glucose Monitoring Adoption

Studies show “user burden” as significant barrier to favorable evaluation of CGM by individuals with diabetes and their caregivers.
December 12, 2017 San Diego, CA – RESEARCH ARTICLE - RE Engler et al. “Adoption Barriers for Continuous Glucose Monitoring and Their Potential Reduction with a Fully Implanted System: Results from Patient Preference Surveys,” Clinical Diabetes 2017 Nov; cd170053. https://doi.org/10.2337/cd17-0053
GlySens® Incorporated today announced the publication of new data in Clinical Diabetes from two recent patient preference studies, providing further support for a proposed 1-year, fully implanted CGM device, with no skin-attached components, currently in development.


According to the data, adult participants and parents of children with diabetes, most frequently sited four factors when deciding to employ CGM: 1) to improve glycemic control (83%), 2) lower A1C (54%), 3) to avoid hypoglycemia (53%) and 4) physician recommendation (42%). Among participants who had never used CGM, key impediments for not trying were 1) cost, 2) having a device attached to the body, and 3) expectations of discomfort when wearing. Interestingly, current and past Adult CGM users confirmed many of these expectations, reporting having problems sometimes or often with the appearance of CGM on the body, discomfort while wearing, insertion pain and skin irritation. Parents of children reported these same issues with greater frequency than adults. “These data suggest that certain people with diabetes are willing (at least initially) to tolerate obtrusive features because of their tremendous motivation to improve their health” said Robert Engler, MD. “It is clear, with our survey of over 1,000 individuals, that a CGM system which eliminates the obtrusiveness of on-body components would enjoy significant up-take among the general patient population.”


Glucose control is key to preventing both short-term and long-term complications of diabetes. A 1% reduction in A1C results in a reduction in the risk of long-term complications like stroke, heart disease, eye damage and kidney disease reduces by 40%.1 A fully implanted CGM sensor with minimal maintenance paired with an external display device, could offer an unobtrusive tool for uncompromised glucose management. The long-term, Eclipse® ICGM® is designed to empower individuals with diabetes by providing the information they need, while freeing them to live life on their own terms.

About GlySens Incorporated

GlySens Incorporated is a privately held corporation devoted to developing the world’s first unobtrusive, truly long term continuous glucose monitoring system, intended to dramatically improve and simplify the lives of people with diabetes. The GlySens fully implanted sensor wirelessly communicates to an external receiver, designed to provide continuous, at-a-glance glucose reporting and alerts regarding hypo- and hyperglycemic glucose excursions. While other CGM approaches may require calibration multiple-times-per-day and demand continuous wearing of through-the-skin or skin-attached components, the calibration checks of the GlySens sensor are designed to be required only infrequently, freeing users from burdensome care and maintenance requirements. For people living with diabetes, the GlySens implantable continuous glucose monitoring system (the GlySens ICGM system) is intended to provide a means for easy, unobtrusive, worry-free glucose monitoring, and empower users by providing the information they need, while freeing them to live life on their own terms—“Live more, worry less.” Additional information is available at www.glysens.com.

Eclipse, ICGM and GlySens are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
Caution – INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.

1 The post-trial monitoring results: 10 years follow up: Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-1589.
3931 Sorrento Valley Blvd
Suite 110
San Diego, CA 92121
Ph: +1 (858) 638-7708
Fax: +1 (858) 638-7727

TechnologyNews RoomCareersContact Us

© 2018 GlySens Incorporated. All Rights Reserved.
Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.
GlySens®, Eclipse®, and ICGM® are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
Terms of UsePrivacy Policy
map-markercogsphonelinkedinslidesharenewspaper-omenu